Raymond James & Associates Altimmune, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALT
# of Institutions
189Shares Held
42.3MCall Options Held
1.05MPut Options Held
582K-
Black Rock Inc. New York, NY5.32MShares$35.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.91MShares$33.1 Million0.0% of portfolio
-
State Street Corp Boston, MA3.91MShares$26.3 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.22MShares$21.7 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$18.5 Million2.23% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $330M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...